Skip to main content
Top
Published in: Infection 2/2015

Open Access 01-04-2015 | Original Paper

In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens

Authors: F. S. Rossmann, A. Kropec, D. Laverde, F. R. Saaverda, D. Wobser, J. Huebner

Published in: Infection | Issue 2/2015

Login to get access

Abstract

Purpose

We compared different immunoglobulin preparations containing IgG (Intraglobin/Intratect) or a mixture of IgG, IgA, and IgM (Pentaglobin) to assess the opsonic and protective efficacy of human immunoglobulin preparations against multiresistent nosocomial pathogens.

Materials and methods

Clinical isolates of E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, Enterococcus faecium, and Staphylococcus aureus were tested by opsonophagocytic assay using immunologobulin preparations at dilutions usually obtained in patients. The target antigens of opsonic antibodies were characterized by opsonophagocytic inhibition assays, and the protective efficacy in vivo was tested in a mouse bacteremia model as previously described.

Results

All strains were killed to at least 50 % by Pentaglobin. One P. aeruginosa strain was not efficiently killed by Intraglobin (23 %) but the other strains were killed by Intraglobin to a similar degree compared to Pentaglobin. Opsonic IgG antibodies against E. faecalis were directed against LTA, while opsonic antibodies in Pentaglobin were primarily directed against other cell wall carbohydrates. In a mouse bacteremia model, Pentaglobin was more protective than Intratect against Staphylococcus aureus, while Intratect reduced colony counts better than normal rabbit serum or saline.

Conclusions

All tested human immunoglobulin preparations contain opsonic and protective antibodies against targets present on multiresistant Gram-positive and Gram-negative bacteria. Enrichment of these preparations with IgM increases the protective efficacy against some strains, probably due to antibodies directed against cell wall carbohydrates.
Literature
2.
go back to reference Huebner J, Arciola CR. Cave enterococcum! Int J Artif Organs. 2007;30:852–3.PubMed Huebner J, Arciola CR. Cave enterococcum! Int J Artif Organs. 2007;30:852–3.PubMed
3.
go back to reference Fabretti F, Huebner J. Implant infections due to enterococci: role of capsular polysaccharides and biofilm. Int J Artif Organs. 2005;28:1079–90.PubMed Fabretti F, Huebner J. Implant infections due to enterococci: role of capsular polysaccharides and biofilm. Int J Artif Organs. 2005;28:1079–90.PubMed
4.
go back to reference Koch S, Hufnagel M, Theilacker C, Huebner J. Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine. 2004;22:822–30.CrossRefPubMed Koch S, Hufnagel M, Theilacker C, Huebner J. Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine. 2004;22:822–30.CrossRefPubMed
5.
go back to reference Talbot GH, Bradley JS, Edwards JE, Rice LB, Spellberg B. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.CrossRefPubMed Talbot GH, Bradley JS, Edwards JE, Rice LB, Spellberg B. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.CrossRefPubMed
6.
go back to reference Fox JL. Anti-infective monoclonals step in where antimicrobials fail. Nat Biotechnol. 2013;31:952–4.CrossRefPubMed Fox JL. Anti-infective monoclonals step in where antimicrobials fail. Nat Biotechnol. 2013;31:952–4.CrossRefPubMed
7.
go back to reference Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–6.CrossRefPubMed Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–6.CrossRefPubMed
8.
go back to reference Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood. 2004;104:3647–54.CrossRefPubMedCentralPubMed Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood. 2004;104:3647–54.CrossRefPubMedCentralPubMed
9.
go back to reference Theilacker C, Kaczynski Z, Kropec A, Fabretti F, Sange T, Holst O, et al. Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid. Infect Immun. 2006;74:5703–12.CrossRefPubMedCentralPubMed Theilacker C, Kaczynski Z, Kropec A, Fabretti F, Sange T, Holst O, et al. Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid. Infect Immun. 2006;74:5703–12.CrossRefPubMedCentralPubMed
10.
go back to reference Theilacker C, Sanchez-Carballo P, Toma I, Fabretti F, Sava I, Kropec A, et al. Glycolipids are involved in biofilm accumulation and prolonged bacteraemia in Enterococcus faecalis. Mol Microbiol. 2009;71:1055–69.CrossRefPubMed Theilacker C, Sanchez-Carballo P, Toma I, Fabretti F, Sava I, Kropec A, et al. Glycolipids are involved in biofilm accumulation and prolonged bacteraemia in Enterococcus faecalis. Mol Microbiol. 2009;71:1055–69.CrossRefPubMed
11.
go back to reference Hufnagel M, Koch S, Creti R, Baldassarri L, Huebner J. A putative sugar-binding transcriptional regulator in a novel gene locus in Enterococcus faecalis contributes to production of biofilm and prolonged bacteremia in mice. J Infect Dis. 2004;189:420–30.CrossRefPubMed Hufnagel M, Koch S, Creti R, Baldassarri L, Huebner J. A putative sugar-binding transcriptional regulator in a novel gene locus in Enterococcus faecalis contributes to production of biofilm and prolonged bacteremia in mice. J Infect Dis. 2004;189:420–30.CrossRefPubMed
12.
go back to reference Theilacker C, Kropec A, Hammer F, Sava I, Wobser D, Sakinc T, et al. Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J Infect Dis. 2012;205:1076–85.CrossRefPubMed Theilacker C, Kropec A, Hammer F, Sava I, Wobser D, Sakinc T, et al. Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J Infect Dis. 2012;205:1076–85.CrossRefPubMed
13.
go back to reference Theilacker C, Kaczynski Z, Kropec A, Sava I, Ye L, Bychowska A, et al. Serodiversity of opsonic antibodies against Enterococcus faecalis—glycans of the cell wall revisited. PLoS One. 2011;6:e17839.CrossRefPubMedCentralPubMed Theilacker C, Kaczynski Z, Kropec A, Sava I, Ye L, Bychowska A, et al. Serodiversity of opsonic antibodies against Enterococcus faecalis—glycans of the cell wall revisited. PLoS One. 2011;6:e17839.CrossRefPubMedCentralPubMed
14.
go back to reference Huebner J, Wang Y, Krueger WA, Madoff LC, Martirosian G, Boisot S, et al. Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun. 1999;67:1213–9.PubMedCentralPubMed Huebner J, Wang Y, Krueger WA, Madoff LC, Martirosian G, Boisot S, et al. Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun. 1999;67:1213–9.PubMedCentralPubMed
15.
go back to reference Sava IG, Zhang F, Toma I, Theilacker C, Li B, Baumert TF, et al. Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J Biol Chem. 2009;284:18194–201.CrossRefPubMedCentralPubMed Sava IG, Zhang F, Toma I, Theilacker C, Li B, Baumert TF, et al. Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J Biol Chem. 2009;284:18194–201.CrossRefPubMedCentralPubMed
16.
go back to reference Kropec A, Sava IG, Vonend C, Sakinc T, Grohmann E, Huebner J. Identification of SagA as a novel vaccine target for the prevention of Enterococcus faecium infections. Microbiology. 2011;157:3429–34.CrossRefPubMed Kropec A, Sava IG, Vonend C, Sakinc T, Grohmann E, Huebner J. Identification of SagA as a novel vaccine target for the prevention of Enterococcus faecium infections. Microbiology. 2011;157:3429–34.CrossRefPubMed
17.
go back to reference Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol. Nature Publishing Group; 2012;12:709–19. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol. Nature Publishing Group; 2012;12:709–19.
18.
go back to reference Hufnagel M, Sixel K, Hammer F, Kropec A, Sava IG, Theilacker C, et al. Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations. Infection. Springer Berlin Heidelberg; 2014;42:749–55. Hufnagel M, Sixel K, Hammer F, Kropec A, Sava IG, Theilacker C, et al. Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations. Infection. Springer Berlin Heidelberg; 2014;42:749–55.
19.
go back to reference Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. In: Ohlsson A, editor. Cochrane database of systematic reviews (Online). Chichester: John Wiley & Sons, Ltd; 2013;7:CD000361. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. In: Ohlsson A, editor. Cochrane database of systematic reviews (Online). Chichester: John Wiley & Sons, Ltd; 2013;7:CD000361.
20.
go back to reference Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27:167–71.CrossRefPubMed Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27:167–71.CrossRefPubMed
22.
go back to reference Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13:655–92.CrossRefPubMed Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13:655–92.CrossRefPubMed
23.
go back to reference Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20:239–49.CrossRefPubMed Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20:239–49.CrossRefPubMed
24.
go back to reference Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit Care. 2002;6:357–62.CrossRefPubMedCentralPubMed Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit Care. 2002;6:357–62.CrossRefPubMedCentralPubMed
25.
go back to reference Barratt-Due A, Sokolov A, Gustavsen A, Hellerud BC, Egge K, Pischke SE, et al. Polyvalent immunoglobulin significantly attenuated the formation of IL-1β in Escherichia coli-induced sepsis in pigs. Immunobiology. Elsevier GmbH; 2013;218:683–9. Barratt-Due A, Sokolov A, Gustavsen A, Hellerud BC, Egge K, Pischke SE, et al. Polyvalent immunoglobulin significantly attenuated the formation of IL-1β in Escherichia coli-induced sepsis in pigs. Immunobiology. Elsevier GmbH; 2013;218:683–9.
26.
go back to reference Norrby-Teglund A, Kotb M. Cytokine patterns in severe invasive group A streptococcal infections. In: Kotb M, Calandra T, editors. Cytokines and chemokines in infectious diseases handbook. Humana Press Inc; 2003. pp. 77–92. Norrby-Teglund A, Kotb M. Cytokine patterns in severe invasive group A streptococcal infections. In: Kotb M, Calandra T, editors. Cytokines and chemokines in infectious diseases handbook. Humana Press Inc; 2003. pp. 77–92.
27.
go back to reference Heikens E, Bonten MJM, Willems RJL. Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol. 2007;189:8233–40.CrossRefPubMedCentralPubMed Heikens E, Bonten MJM, Willems RJL. Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol. 2007;189:8233–40.CrossRefPubMedCentralPubMed
28.
go back to reference Pang YY, Schwartz J, Thoendel M, Ackermann LW, Horswill AR, Nauseef WM. agr-Dependent interactions of Staphylococcus aureus USA300 with human polymorphonuclear neutrophils. J Innate Immun. 2010;2:546–59.CrossRefPubMedCentralPubMed Pang YY, Schwartz J, Thoendel M, Ackermann LW, Horswill AR, Nauseef WM. agr-Dependent interactions of Staphylococcus aureus USA300 with human polymorphonuclear neutrophils. J Innate Immun. 2010;2:546–59.CrossRefPubMedCentralPubMed
29.
go back to reference Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55:582–6.CrossRefPubMed Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55:582–6.CrossRefPubMed
Metadata
Title
In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens
Authors
F. S. Rossmann
A. Kropec
D. Laverde
F. R. Saaverda
D. Wobser
J. Huebner
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0706-1

Other articles of this Issue 2/2015

Infection 2/2015 Go to the issue